Blinded independent central review of oncology trials: the monitoring of reader performance

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis™ we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

Poster presented at the ESMO Asia meeting – November 20-22, 2020 The poster presents results from a study dealing with inter-reader discrepancies in image-based oncology trials in BICR settings. Inter-reader discrepancy is a metric of choice for detecting quality issues in clinical trials. The study provides reference values metrics to monitor reader performance with double read plus adjudication in clinical trials using RECIST 1.1.